Project Grant R21AI192086

Award Date 5/22/25
Completion Date 4/30/27
Dollars Obligated $210K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $193,316 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Boston Medical Center Corporation (BMC) to study the relationship between HIV exposure, contact networks, and tuberculosis (TB) in children under 5 years old. The award period runs from August 20, 2024 to July 31, 2029. The grant supports research activities focused on understanding how HIV exposure, social contact...
This federal Project Grant award, valued at $899,894 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports scientific research on understanding the interactions between macrophages, neutrophils, and HIV that contribute to tuberculosis (TB) disease progression. The key products and services to be delivered under this grant include: Defining the type I interferon (IFN) signaling and...
This $517,185 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund a research project to characterize the immune response to tuberculosis (TB) using integrated single-cell genomics and ancestry-adjusted expression quantitative trait loci (eQTL) mapping. The project will analyze peripheral blood mononuclear cells (PBMCs) collected from 225 individuals across three critical TB disease states...
This $146,170 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support a global framework of activities to grow interdisciplinary research on tuberculosis (TB) and undernutrition. The project aims to primarily assist junior faculty engaging in global health research through mentoring, development of new scientific methodologies, and leadership growth. The framework will...
This $2,817,044 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports a research program titled "Systems Genetics of Tuberculosis". The program aims to leverage new mouse and bacterial genetic resources to study the complex interactions between host diversity and pathogen variation that influence tuberculosis (TB) infection outcomes and vaccine efficacy. Key products and services to be...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $787,171 to develop a new class of anti-tuberculosis (TB) compounds. The award supports research to discover and optimize 1,2,4-triazole and pyrrolidine compounds that inhibit the growth of drug-resistant strains of Mycobacterium tuberculosis, the causative agent of TB. The research aims to understand the...
This federal Project Grant award, valued at $774,881, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to develop pro-apoptotic (cell death-inducing) drugs as host-directed therapies to shorten treatment for drug-susceptible and multi-drug resistant pulmonary tuberculosis (TB), as well as prevent post-TB lung disease. The project will leverage advanced in vivo imaging...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $127,980 to The Johns Hopkins University to conduct research aimed at improving tuberculosis (TB) detection and prevention in high-burden settings. The key products and services to be delivered under this 5-year award include: 1) Refining estimates of subnational TB prevalence by synthesizing emerging...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Trustees of Boston University, doing business as Boston University Medical Campus, to characterize the burden, severity, and phenotypic presentation of post-tuberculosis lung disease (PTLD) and its association with interleukin-6 (IL-6) signaling pathways in tuberculosis (TB) patients with and without HIV. The total award amount is...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,413,412 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Texas Biomedical Research Institute. The grant, titled "Mechanisms of Efficient Control of Mycobacterium Tuberculosis in the Lungs Prior to Granuloma," aims to develop novel vaccination strategies to contain the tuberculosis pandemic. The research will use cutting-edge techniques like single-cell RNA...

This $209,750 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will leverage antibody-based approaches to prevent and detect tuberculosis (TB) in children affected by HIV. The key goals are to: 1) Define antibody Fc features associated with protection from Mycobacterium tuberculosis (MTB) infection in infants with and without maternal HIV exposure, and 2) Identify biomarkers for active TB and MTB infection compared to uninfected controls. The research will utilize specimen repositories from pediatric cohorts in Kenya, South Africa, India, and a multi-center IMPAACT study. The findings are expected to advance the development of innovative public health strategies, including new maternal/infant vaccines, monoclonal antibody therapies, and point-of-care testing for MTB infection and TB disease in high-burden settings. This multidisciplinary project capitalizes on Emory University's extensive expertise in humoral immunity, TB research, and assay development.

Generated 6/17/25, 3:40 AM